

All MCOs: Change in Preferred Drug List Status for Stimulants and Related Agents Drug Class Effective July 29, 2026

Background:

Due to a potential supply gap, Sandoz is currently allocating brand-name Ritalin LA products resulting in a product backorder. In response, the Texas Health and Human Services Commission temporarily removed the non-preferred status from certain generic Ritalin LA products on the preferred drug list (PDL).

Key Details:

HHSC temporarily removed the non-preferred status for the following drugs in the attached "Stimulants and Related Agents" table, effective July 29, 2026.

These changes allow providers to prescribe certain generic Ritalin LA products without the requirement of a PDL prior authorization and continue access to necessary medication for members.

MCOs should be in compliance with this status removal as of July 31, 2026.

Resources:

Attachments:	Stimulants and Related Agents
---------------------	-------------------------------

Contact:

Vdp-formulary@hhs.state.tx.us
